| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.07M | 4.90M | 10.91M | 10.03M | 8.48M | 7.10M |
| Gross Profit | 1.05M | 1.34M | 3.89M | 4.44M | 3.27M | 1.59M |
| EBITDA | -4.18M | -2.23M | -2.46M | -2.48M | 19.00K | -4.22M |
| Net Income | -3.28M | -2.72M | -3.71M | -3.99M | -1.43M | -6.09M |
Balance Sheet | ||||||
| Total Assets | 10.22M | 10.05M | 10.39M | 13.62M | 15.66M | 19.13M |
| Cash, Cash Equivalents and Short-Term Investments | 643.00K | 1.26M | 383.00K | 1.65M | 3.13M | 3.29M |
| Total Debt | 1.07M | 1.26M | 889.00K | 1.22M | 1.47M | 3.09M |
| Total Liabilities | 6.85M | 4.79M | 3.23M | 2.79M | 3.04M | 5.34M |
| Stockholders Equity | 3.38M | 5.26M | 7.16M | 10.83M | 12.62M | 13.79M |
Cash Flow | ||||||
| Free Cash Flow | -2.22M | -2.20M | -1.21M | -3.53M | -3.80M | -1.66M |
| Operating Cash Flow | -2.21M | -2.15M | -1.11M | -2.69M | -3.43M | -1.50M |
| Investing Cash Flow | -14.00K | 2.24M | -181.00K | -842.00K | 5.08M | -159.00K |
| Financing Cash Flow | 792.00K | 792.00K | 0.00 | 2.04M | -2.24M | 1.30M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | £53.81M | 6.47 | 6.87% | ― | 7.16% | -11.00% | |
66 Neutral | £350.64M | 20.59 | 11.19% | 0.77% | 8.66% | 9.47% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
63 Neutral | £119.64M | -3.44 | 15.77% | ― | -5.73% | ― | |
51 Neutral | £41.77M | -70.33 | -64.09% | ― | -0.25% | -84.33% | |
46 Neutral | £11.45M | -1.16 | ― | ― | ― | ― | |
44 Neutral | £394.50M | -8.61 | -18.47% | ― | 57.73% | -67.12% |
MYCELX Technologies reported that it achieved profitability in 2025, with expected full-year revenue of about $11.7 million, up 140% year-on-year, and EBITDA and profit before tax significantly ahead of market expectations, reflecting strict cost control, operating leverage and a shift toward higher-margin revenue. The company enters 2026 with a stronger earnings profile, streamlined organisation and growing commercial momentum in its core markets, while refining its strategic focus on produced water, PFAS remediation and water services, strengthening its executive team, and planning new engineering and business development hires to accelerate growth in key regions such as the Permian Basin and the Middle East, with implications for improved cash generation and long-term value creation for stakeholders.
The most recent analyst rating on (GB:MYX) stock is a Sell with a £26.00 price target. To see the full list of analyst forecasts on MyCelx Technologies stock, see the GB:MYX Stock Forecast page.
MYCELX Technologies Corporation has secured a $3.9 million project to supply its REGEN water treatment system in the US Permian Basin, a key oil-producing region. This project, expected to be delivered in 2026, highlights MYCELX’s expanding influence in the region and the industry’s confidence in its technology. Additionally, MYCELX’s presentation at a Middle East symposium showcased the successful implementation of its REGEN Retrofit Package in Oman, further solidifying its reputation for addressing complex water treatment challenges globally.